Immunovant’s $450M; Oncopeptides reassesses Pepaxti strategy in Europe; Akebia resubmits kidney drug

Immunovant goes for $450M: Immunovant’s early-stage autoimmune data will lead to a $450 million haul for the New York biotech, about $150 million more than initially announced on Tuesday. Immunovant said Wednesday it plans to sell 7.37 million shares $IMVT at $38 apiece in a public offering and sell another 4.47 million to its parent, Roivant Sciences. The early clinical data for Immunovant’s anti-FcRn IMVT-1402 sent the company’s shares soaring on Tuesday and also boosted Roivant’s stock price. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Chronic stress disrupts gut microbiota, promoting colorectal cancer growth

Cutting-edge research has uncovered how chronic stress disrupts the balance of gut microbiota to speed up the progression of colorectal cancer (CRC), opening new avenues

October 14, 2024

After Appalachian hospitals merged into a monopoly, their ERs slowed to a crawl

In the small Appalachian city of Bristol, Virginia, City Council member Neal Osborne left a meeting on the morning of Jan. 3 and rushed himself

March 25, 2024

Kenvue, Walgreens and others named in class action lawsuits over efficacy of nasal decongestant

Several manufacturers of over-the-counter cold medicines have been named in a string of class action lawsuits following an FDA advisory committee’s vote earlier this week

September 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.